Written in May 2024
Hello, future scientists! Welcome to "Science Unveiled," your go-to blog for making science fun and easy to understand. Today, we are diving into a topic that sounds straight out of a science fiction movie: Gene Therapy. Imagine a world where we could use the very blueprint of life, our genes, to cure diseases and improve health. Sounds too good to be true, right? Well, let us explore Gene Therapy together!
As you read through this blog, you will come across the following sections. Enjoy!
Explore fundamentals clearly and understandably.
Engage in thought-provoking questions and discussions. Reflect on ethical implications, future possibilities, and how it might impact society.
Delve deeper into complexities! Gain insights into advanced techniques, current research, and ongoing challenges in the field.
References provide the sources and scholarly works consulted for information and citations throughout this article.
Gene Therapy Broken Down!
First of All, What is Gene Therapy?
Gene Therapy is a cutting-edge technique where genes inside your body's cells are altered to treat and prevent diseases. Genes are instructions for building proteins, which do most of the work in our cells. However, these instructions have errors sometimes, leading to genetic disorders. That is where Gene Therapy comes in; Gene Therapy aims to fix these errors by inserting a healthy copy of the gene, silencing a faulty gene, or even adding a new gene altogether!
How Does Gene Therapy Work?
There are several gene therapy methods, but they all use one central concept: delivering the correct genetic material to the proper cells. To do this, scientists use vectors, which you can think of as vehicles for transporting the new gene into the cells. The most common vectors are viruses because they are very good at entering cells. Don't worry—these viruses are modified so they cannot cause disease!
There are two main methods of Vector Delivery Systems for gene therapy.
In Vivo Gene Therapy
The vector is directly inserted into the patient's body in this method. It will then find its way into the correct target cells and deliver the proper genetic material. Though this offers immediate therapeutic effects, there is a potential for off-target effects as it limits targeting precision and doesn't account for possible immune responses against viral vectors.
Ex Vivo Gene Therapy
In this approach, scientists extract the correct cells from the patient, modify them in the lab to contain the new gene, and then reintroduce these modified cells back into the patient's body. Though this approach allows for precise genetic modification in controlled settings and enables targeted delivery, this method is cost and time-intensive and may trigger immune responses against reintroduced cells.
Gene Editing Technologies
In gene editing, precise modifications at specific sites in the genome are involved. CRISPR-Cas9 is a revolutionary technology that allows scientists to edit parts of the genome by removing, adding, or altering sections of the DNA sequence.
Success Stories in Gene Therapy
Gene therapy has already shown promise in treating many severe conditions, such as:
Severe Combined Immunodeficiency (SCID): Sometimes referred to as "bubble boy disease," SCID is a severe genetic disorder that impacts the immune system. Gene therapy has successfully treated children with this condition, allowing them to live normal lives without a matched sibling donor.
Inherited Retinal Diseases: Conditions like Leber congenital amaurosis can lead to blindness. Gene therapy has been used to restore vision in some patients with these genetic eye disorders
Hemophilia: This genetic disorder affects the blood's ability to clot, causing patients to bleed more and can damage their organs and joints. Gene therapy has made it possible for patients to produce the necessary clotting factors, reducing their reliance on regular injections.
The Future of Gene Therapy
The future of gene therapy is fascinating and incredibly exciting. Now, scientists are exploring ways to treat an even wider range of diseases, varying from cystic fibrosis to certain types of cancer. Advances in CRISPR-Cas9 technology, a powerful and emerging tool for editing genes, are paving the way for even more precise and effective treatments.
Challenges and Ethical Considerations
As with any powerful technology, gene therapy comes with its own set of challenges and ethical considerations. First of all, safety is a significant concern. This is because introducing new genes into the body could have unintended and harmful side effects or trigger adverse immune responses. Secondly, many question the accessibility and fairness of this tool. Ensuring that these life-saving treatments are available to everyone who needs them is a critical challenge, as it is only fair that advancements in medical science benefit all individuals. Ethical debates also arise around the idea of "designer babies", which refers to the concept of using gene-editing technologies to select or alter specific traits in embryos, and the potential for genetic enhancements
Conclusion
Gene therapy has the potential to revolutionize medicine. By understanding and manipulating our genetic code, we can treat and even cure diseases that were once thought to be incurable. While many challenges remain, the progress made so far is truly remarkable.
What Do You Think?
Let's hear your voice! Share your thoughts on gene therapy! Spark conversations in the comment section at the bottom of our page and see how your views compare with others in our community.
*after this, go see the Deep Dive section to gain insights into advanced techniques, current research, and ongoing challenges in the field.
Polls and Surveys
1. Do you believe gene therapy will become a mainstream treatment option in the next decade?
Yes
No
Write an answer
Do you think gene editing should be used in agriculture to produce more resilient crops?
Absolutely!
Only if it’s proven safe
No, I prefer natural methods
Would you consider undergoing gene therapy if it could prevent a serious illness?
Yes
Only after more research
Absolutely not
How well do you understand the science behind gene editing? Are you familiar with technologies like CRISPR?
Expert level
I know the basics
Not much at all
Soon to be expert😁 I'll read Science Unveiled's CRISPR post
Discussion Questions:
Is it ethical to use gene therapy to alter non-medical traits, such as intelligence or physical appearance, in humans?
Should gene therapy be accessible only to those who can afford it, or should it be universally available regardless of socioeconomic status?
Case Study
DISCLAIMER: The case studies presented in this blog are entirely fictional and are created for educational purposes only! They are not based on real individuals, events, or organizations. Any resemblance to actual persons —living or dead— or actual events is purely coincidental.
John is a 30-year-old man and was recently diagnosed with Huntington's disease, a genetic disorder that causes progressive deterioration of brain cells. John's mother passed away from the same disease, and he has a 50% chance of inheriting the mutated gene from his parent. Genetic testing confirms that John has indeed inherited the mutated gene and is likely to develop symptoms in the coming years. John learns about a clinical trial for a gene therapy that seeks to slow down or halt the progression of Huntington's disease. The treatment involves injecting a virus carrying a healthy copy of the gene into the brain to replace the faulty gene responsible for the disease. The trial is in its early stages, and while initial results show promise in animal models, the long-term effectiveness and safety in humans are still unsure.
What information must John fully understand before consenting to the clinical trial?
How might participating in the gene therapy trial impact John's quality of life compared to living with the progression of this disease?
Deep Dive!
Advanced Mechanisms and Strategies
Vector design has evolved dramatically. In addition to basic viral vectors, synthetic and hybrid vectors are now incorporated. Scientists are developing more targeted systems to develop and select specific target cell types so that off-target effects can be reduced and efficiency enhanced.
In Hybrid Vectors, characteristics of viral and non-viral systems are combined to maximize efficiency while minimizing unwanted immune responses.
In Capsid Engineering, the protein shells of viruses are modified to have better-delivering capabilities to evade the host immune system.
Tissue-Specific Promoters
Recent advancements in gene therapy involve tissue-specific promoters, which ensure gene expression only occurs in targeted tissues. This approach is necessary for diseases where the expression of therapeutic genes requires tight regulation to mimic natural physiology and avoid ectopic effects. The use of this new technology will allow for more precision and help to treat a wider variety of diseases.
MicroRNA Therapies
MicroRNA (miRNA) recognition sequences are being integrated into therapy vectors. This allows for the enhancement of gene expression based on cellular environments. This will significantly improve safety profiles in Gene Therapy.
Safety Protocol and Considerations
Rigorous clinical trials are necessary to ensure safety and efficacy. These trials include:
Phase I - Safety is prioritized, and appropriate dosages are determined while monitoring side effects.
Phase II - Efficacy is a main focus. A larger cohort is involved in assessing the therapeutic benefits (positive health outcomes and improvements)
Phase III - A comparison of new therapy and existing treatment is conducted to evaluate situations on a larger scale.
Gene Drive Technology
Gene drive systems are an approach that promotes the inheritance of particular genes to increase their prevalence in a population. This technique is being explored to control vector-borne diseases such as malaria by spreading modified genes through wild mosquito populations. The goal of spreading these modified genes through reproductive processes is to alter mosquito populations to reduce their ability to transmit diseases such as malaria, contributing to disease control efforts on broader scales. Gene drive systems offer promising solutions to the issue of effective and precise delivery and maintenance of genes in desired cells by leveraging natural genetic inheritance mechanisms to promote the propagation of therapeutic genes within a patient's body.
Synthetic Biology
Synthetic biology offers tools for creating entirely new biological systems or redesigning existing systems for better functionality. In gene therapy, synthetic circuits can be designed to control gene expression dynamically in response to environmental factors. This can offer precise control over therapeutic gene activity and minimize unintended effects.
Broadening the Scope to Complex Diseases
Initial gene therapies target single-gene disorders. However, there is now growing interest in treating more complex conditions such as Alzheimer's disease, cardiovascular diseases, and multi-genetic disorders. While still in the investigational stages, the pursuit of multi-gene therapies and combination approaches is continued.
Immunogenicity and Durability Issues
Another hurdle in gene therapy is the host's immune response to the viral vectors often used. Over time, this leads to the rejection of the therapy and limits its effectiveness due to the development of antibodies. Research is focused on developing immune-evasive strategies and exploring alternative delivery methods.
References
American Society of Gene + Cell Therapy. (2022, January 6). Gene Therapy Basics | ASGCT - American Society of Gene & Cell Therapy |. Patienteducation.asgct.org. https://patienteducation.asgct.org/gene-therapy-101/gene-therapy-basics
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., Petersen-Jones, S., Bhattacharya, S. S., Thrasher, A. J., Fitzke, F. W., Carter, B. J., Rubin, G. S., Moore, A. T., & Ali, R. R. (2008). Effect of Gene Therapy on Visual Function in Leber’s Congenital Amaurosis. New England Journal of Medicine, 358(21), 2231–2239. https://doi.org/10.1056/nejmoa0802268
Bhatia, S., Yann Le Cam, Carrion, J., Diamond, L., Fennessy, P., Gassman, S., Gutzwiller, F., Kagan, S., Pankevich, D., Jennifer Young Maloney, Nitin Mahadev, Schulz, M., Durhane Wong-Rieger, & Morgese, P. (2024). Strengthening health systems for access to gene therapy in rare genetic disorders. Molecular Therapy. Methods & Clinical Development, 32(2), 101220–101220. https://doi.org/10.1016/j.omtm.2024.101220
Doudna, J. A., & Charpentier, E. (2014). The New Frontier of Genome Engineering with CRISPR-Cas9. Science, 346(6213), 1258096–1258096. https://doi.org/10.1126/science.1258096
Jahangiri, S., Rahimnejad, M., Boroujeni, N. N., Ahmadi, Z., Fath, P. M., Ahmadi, S., Safarkhani, M., & Rabiee, N. (2022). Viral and Non‐viral Gene Therapy using 3D (Bio)printing. The Journal of Gene Medicine. https://doi.org/10.1002/jgm.3458
Mayo Clinic. (2017, December 29). Gene therapy. Mayo Clinic. https://www.mayoclinic.org/tests-procedures/gene-therapy/about/pac-20384619
Munung, N. S., Nnodu, O. E., Moru, P. O., Kalu, A. A., Impouma, B., Treadwell, M. J., & Wonkam, A. (2023). Looking ahead: ethical and social challenges of somatic gene therapy for sickle cell disease in Africa. Gene Therapy, 1–7. https://doi.org/10.1038/s41434-023-00429-7
Scheller, E. L., & Krebsbach, P. H. (2009). Gene Therapy: Design and Prospects for Craniofacial Regeneration. Journal of Dental Research, 88(7), 585–596. National Library of Medicine. https://doi.org/10.1177/0022034509337480
St. Jude gene therapy cures babies with “bubble boy” disease. (2019, April 17). Www.stjude.org. https://www.stjude.org/media-resources/news-releases/2019-medicine-science-news/st-jude-gene-therapy-cures-babies-with-bubble-boy-disease.html
Stock, M., & Gorochowski, T. E. (2024). Open-endedness in synthetic biology: A route to continual innovation for biological design. Science Advances, 10(3). https://doi.org/10.1126/sciadv.adi3621
(n.d.-a). Wolfgang Miesbach, Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Giancarlo Castaman, Joachim Schwäble, Halvard Bonig, Seifried, E., Cattaneo, F., Meyer, C., & Frank. (2018). Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B. Blood, 131(9), 1022–1031. https://doi.org/10.1182/blood-2017-09-804419 .
(n.d.-b). Balachandran, S., Prada-Medina, C. A., Mensah, M. A., Kakar, N., Nagel, I., Jelena Pozojevic, Audain, E., Hitz, M.-P., Kircher, M., Varun K.A. Sreenivasan, & Spielmann, M. (2024). STIGMA: Single-cell tissue-specific gene prioritization using machine learning. American Journal of Human Genetics, 111(2), 338–349. https://doi.org/10.1016/j.ajhg.2023.12.011 .
Remember to share your thoughts in the comments section below! What topics are you eager to explore next? Stay tuned for more exciting insights and other fascinating areas of science.
I think that before consenting to the clinical trial, John must fully understand the purpose, potential risks, benefits, and procedures involved. He should also be aware of his right to withdraw at any time and the confidentiality of his personal information.